Breast Cancer Coverage From Every Angle
Advertisement
Advertisement

Recent News

SABCS 2017: First-Line Ribociclib and Endocrine Therapy in Advanced Breast Cancer
SABCS 2017: Tamoxifen Plus Ovarian Function Suppression Regimen for Early Breast Cancer
Combining Focused Ultrasound and Immunotherapy to Treat Breast Cancer
Effect of Pomegranate Extract on Breast Cancer Stem Cells
FDA Approves Biosimilar to Trastuzumab for HER2-Positive Breast Cancer
Outcomes With Regional Anesthesia in Breast Cancer Surgery
Intermittent Versus Continuous Chemotherapy Scheduling in Metastatic Breast Cancer
Benefits Reported for Breast Cancer Patients Who Regularly Practice Yoga
Influence of Race, Insurance Status, and Accessibility on Immediate Breast Reconstruction Rates
Combination of Alisertib and TAK-228 in Triple-Negative Breast Cancer
New Indication for Fulvestrant in Combination Therapy for Advanced Breast Cancer
AORTIC 2017: Are Skin Lighteners and Hair Relaxers Associated With Increased Risk of Breast Cancer?
First-Line Ribociclib and Letrozole in Advanced Breast Cancer
Are Standard-of-Care Treatments in Clinical Trials Really ‘Standard’?
AACR-NCI-EORTC 2017: Potential of Antibiotic Salinomycin in Breast Cancer
CoBrCa 2017: Ovarian Function Suppression Plus AI in Young Women at Risk of Breast Cancer Recurrence
AACR-NCI-EORTC 2017: Potential Novel Agent for Estrogen Receptor–Positive Breast Cancer
CoBrCa 2017: Genetic Testing for Women With Breast Cancer
ACS 2017: Can Socioeconomic Status Predict Quality of Life in Breast Cancer Survivors?
ACS 2017: Women at Higher Risk of Breast Cancer and MRI Screening
Intravenous Rolapitant Approved by FDA for Delayed Chemotherapy-Induced Nausea and Vomiting
FDA Grants Priority Review for Olaparib in Metastatic Breast Cancer
Novel Strategies for Preventing Chemotherapy-Induced Peripheral Neuropathy
Fertility Preservation in BRCA-Positive Women With Breast Cancer
Priority Review Granted by FDA for Abemaciclib as First-Line Treatment for Advanced Breast Cancer
Further Efficacy Outcomes From OlympiAD Trial of Olaparib in Advanced Breast Cancer
ASTRO 2017: Biologic Markers of Primary Breast Cancer and Brain Metastases
ASTRO 2017: Neoadjuvant Radiation Therapy Before Surgery in Locally Advanced Breast Cancer
Priority Review Granted for Adjuvant Combination Treatment for HER2-Positive Breast Cancer
TIL Levels and Response to Pembrolizumab in Metastatic Triple-Negative Breast Cancer
ASTRO 2017: Stereotactic Radiosurgery for Brain Metastases From Breast Cancer
FDA Approves Abemaciclib for Treatment of Breast Cancers That Progress With Endocrine Therapy
ASTRO 2017: Accelerated Breast Radiation Therapy After Mastectomy
ASTRO 2017: Shorter Course of Radiation Therapy for Younger Women With Breast Cancer
Tumor Microenvironment in Racially Distinct Triple-Negative Breast Cancers
ESMO 2017: Neoadjuvant Letrozole Plus Palbociclib in Luminal Breast Cancer
ESMO 2017: Comparison of Biosimilar ABP 980 and Trastuzumab in HER2-Positive Breast Cancer
ESMO 2017: Extended Adjuvant Neratinib for Early-Stage HER2-Positive Breast Cancer
ESMO 2017: Comparison of Two Adjuvant Therapies for Early Breast Cancer
ESMO 2017: Neoadjuvant Combination Therapy With Taselisib and Letrozole in Early Breast Cancer
ESMO 2017: Adding Abemaciclib to Endocrine Therapy for Advanced Breast Cancer
ESMO 2017: Nivolumab After Induction Therapy in Triple-Negative Breast Cancer
ESMO 2017: Adding Everolimus to Letrozole in Metastatic Breast Cancer Therapy
ESMO 2017: Chemotherapy for Small Node-Negative Breast Tumors
Impact of Surgical Modality on Breast-Specific Sensuality
Triple-Negative Breast Cancer: Genomic Metrics and Immune Infiltration
Mammography Device With Option for Patient-Assisted Compression Cleared by FDA
DS-8201 Granted Breakthrough Therapy Designation for HER2-Positive Metastatic Breast Cancer
FDA Approves Expanded Use of Fulvestrant as Monotherapy in Breast Cancer
Neoadjuvant Radiotherapy for Early-Stage Breast Cancer
ASCO Breast Cancer Guideline Update on Use of 70-Gene Test
Nipple-Sparing Mastectomy and Breast Cancer Recurrence
Risk-Reducing Mastectomy vs. Surveillance for Women With BRCA Mutation and History of Ovarian Cancer
Ado-trastuzumab Emtansine as First-Line Therapy for Metastatic Breast Cancer in MARIANNE Trial
Patient-Reported Outcomes in Relation to Fat Grafting in Postmastectomy Breast Reconstruction
Recent Trends in Male Breast Cancer
Leading Cause of Death in Patients With Breast Cancer
Neratinib Approved by FDA for Extended Adjuvant Treatment of HER2-Positive Breast Cancer
ASCO 2017: Ado-trastuzumab Emtansine in Resistant HER2-Positive Breast Cancer
Priority Review Granted for Abemaciclib in Advanced Breast Cancer
ASCO 2017: First-Line Addition of Bevacizumab to Endocrine Therapy in Advanced Breast Cancer
ASCO 2017: Dual HER2 Blockade in Metastatic Breast Cancer
ASCO 2017: Duration of Adjuvant Trastuzumab for HER2-Positive Breast Cancer
Implementing BRCA1/2 Genetic Testing in Patients With Breast Cancer
ASCO 2017: MONALEESA-2 Update on Combination of Ribociclib and Letrozole
Joint Position Statement on Bone Loss Associated With Aromatase Inhibitors
ASCO 2017: Talazoparib in Metastatic Breast Cancer With a Germline BRCA1/2 Mutation
ASCO 2017: Abemaciclib Plus Fulvestrant in Endocrine-Resistant Breast Cancer
ASCO 2017: Adding a Second HER2 Blocker to Standard of Care in Invasive Breast Cancer
ASCO 2017: Addition of Pembrolizumab to Standard Therapy in High-Risk Breast Cancer
ASCO 2017: Olaparib Monotherapy in Metastatic Breast Cancer
ASCO 2017: Safety of Pregnancy After Breast Cancer
ACOG 2017: Prolonged Tamoxifen vs Oophorectomy in Estrogen Receptor–Positive Breast Cancer
ACOG 2017: Debate Continues Over Timing and Frequency of Breast Cancer Screening
Updated Clinical Practice Guidelines on Integrative Therapies
ASBrS 2017: Is Adjuvant Whole-Breast Radiation Therapy Necessary for Ductal Carcinoma in Situ?
ASBrS 2017: Surgical Resection of Primary Tumors in Stage IV Breast Cancer
FDA Approves Co-Pack of Ribociclib and Letrozole for Metastatic Breast Cancer
IMPAKT 2017: Tumor-Infiltrating Lymphocyte Levels in HER2-Positive Breast Cancer
ASBrS 2017: Practice Patterns in Use of SLND After Neoadjuvant Chemotherapy
IMPAKT 2017: LAR Subtype of Triple-Negative Breast Cancer and CDK4/6 Inhibition
ASBrS 2017: Lumpectomy and Excisional Biopsy in an Outpatient Setting
ASBrS 2017: Risk of Lymphedema Related to Breast Cancer
ASBrS 2017: Contralateral Prophylactic Mastectomy for Ductal Carcinoma in Situ
Use of Dexamethasone Oral Solution in Patients Receiving Treatment for Breast Cancer
Predicting Local Metastases After Neoadjuvant Chemotherapy for Breast Cancer
AACR 2017: Interim Results of Phase Ib/II Trial of Neratinib in Combination With Ado-trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
AACR 2017: Atezolizumab Associated With Survival Benefit in Triple Negative Breast Cancer
Effect of Scalp-Cooling Device on Hair Loss in Women Receiving Chemotherapy for Breast Cancer
Cholesterol-Lowering Medication Use and Breast Cancer Outcome in the BIG 1-98 Trial
Everolimus Added to Fulvestrant Upped PFS in Postmenopausal HR+ Breast Cancer Patients
Buparlisib Phase III Findings: Glass Half Empty or Half Full?